• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Meningococcal serogroup B vaccines: will they live up to expectations?

作者信息

Zollinger Wendell D, Poolman Jan T, Maiden Martin C J

出版信息

Expert Rev Vaccines. 2011 May;10(5):559-61. doi: 10.1586/erv.11.41.

DOI:10.1586/erv.11.41
PMID:21604975
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3985070/
Abstract
摘要

相似文献

1
Meningococcal serogroup B vaccines: will they live up to expectations?B 群脑膜炎球菌疫苗：它们会不负众望吗？
Expert Rev Vaccines. 2011 May;10(5):559-61. doi: 10.1586/erv.11.41.
2
A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.针对 B 群脑膜炎奈瑟球菌疾病的组合重组蛋白和外膜囊泡疫苗。
Expert Rev Vaccines. 2011 May;10(5):575-88. doi: 10.1586/erv.11.32.
3
Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.B 群脑膜炎奈瑟氏球菌抗原的遗传转变与广泛交叉保护疫苗的探索。
Expert Rev Vaccines. 2010 Oct;9(10):1203-17. doi: 10.1586/erv.10.116.
4
Reverse vaccinology--in search of a genome-derived meningococcal vaccine.反向疫苗学——探寻基于基因组的脑膜炎球菌疫苗
Vaccine. 2006 Apr 12;24 Suppl 2:S2-11-2. doi: 10.1016/j.vaccine.2005.01.103.
5
Neisseria meningitidis serogroup B: laboratory correlates of protection.B 群脑膜炎奈瑟菌：保护作用的实验室相关因素
FEMS Immunol Med Microbiol. 2002 Oct 11;34(2):89-96. doi: 10.1111/j.1574-695X.2002.tb00608.x.
6
Recent developments in vaccines to prevent meningococcal serogroup B infections.预防B群脑膜炎球菌感染疫苗的最新进展。
Curr Opin Mol Ther. 2003 Feb;5(1):33-8.
7
Effectiveness of a Serogroup B and C Meningococcal Vaccine Developed in Cuba.古巴研发的 B 群和 C 群脑膜炎球菌疫苗的有效性。
MEDICC Rev. 2018 Jul;20(3):22-29. doi: 10.37757/MR2018.V20.N3.6.
8
Vaccines for prevention of group B meningococcal disease: Not your father's vaccines.预防B群脑膜炎球菌病的疫苗：不是你父辈们用的那些疫苗了。
Vaccine. 2015 Nov 27;33 Suppl 4:D32-8. doi: 10.1016/j.vaccine.2015.05.101. Epub 2015 Jul 2.
9
Two meningococcal B vaccines receive FDA 'breakthrough therapy' designation.
Hum Vaccin Immunother. 2014;10(6):1428-9.
10
Development of a vaccine against serogroup B has been the main scientific challenge. Preface.研发针对B群的疫苗一直是主要的科学挑战。前言。
Vaccine. 2012 May 30;30 Suppl 2:B1-2. doi: 10.1016/j.vaccine.2012.02.006.

引用本文的文献

1
Bacterial Outer Membrane Vesicles (OMVs)-based Dual Vaccine for Influenza A H1N1 Virus and MERS-CoV.基于细菌外膜囊泡（OMVs）的甲型H1N1流感病毒和中东呼吸综合征冠状病毒双价疫苗
Vaccines (Basel). 2019 May 28;7(2):46. doi: 10.3390/vaccines7020046.
2
Meningococcal B vaccine and the vision of a meningitis free world.B 型脑膜炎球菌疫苗与无脑膜炎世界的愿景
J Prev Med Hyg. 2015 Aug 31;56(3):E140-3.
3
A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program.一种多组分B群脑膜炎球菌疫苗（4CMenB）：临床开发计划
Drugs. 2014 Jan;74(1):15-30. doi: 10.1007/s40265-013-0155-7.
4
Adjuvant efficacy of mOMV against avian influenza virus infection in mice.mOMV 对小鼠流感病毒感染的辅助疗效。
J Microbiol. 2013 Oct;51(5):682-8. doi: 10.1007/s12275-013-3411-3. Epub 2013 Oct 31.
5
Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine.青少年接种一剂、两剂或三剂 4CMenB 脑膜炎奈瑟菌 B 型疫苗 18-24 个月后抗体的持久性。
Hum Vaccin Immunother. 2013 Nov;9(11):2304-10. doi: 10.4161/hv.25505. Epub 2013 Jun 28.
6
Improved production process for native outer membrane vesicle vaccine against Neisseria meningitidis.改进针对脑膜炎奈瑟菌的天然外膜囊泡疫苗的生产工艺。
PLoS One. 2013 May 31;8(5):e65157. doi: 10.1371/journal.pone.0065157. Print 2013.
7
Use of a molecular decoy to segregate transport from antigenicity in the FrpB iron transporter from Neisseria meningitidis.利用分子诱饵将脑膜炎奈瑟菌 FrpB 铁转运蛋白的运输功能与其抗原性分离。
PLoS One. 2013;8(2):e56746. doi: 10.1371/journal.pone.0056746. Epub 2013 Feb 15.
8
Cysteine depletion causes oxidative stress and triggers outer membrane vesicle release by Neisseria meningitidis; implications for vaccine development.半胱氨酸耗竭导致氧化应激，并触发脑膜炎奈瑟菌的外膜囊泡释放；对疫苗开发的影响。
PLoS One. 2013;8(1):e54314. doi: 10.1371/journal.pone.0054314. Epub 2013 Jan 23.
9
Refolding, purification and crystallization of the FrpB outer membrane iron transporter from Neisseria meningitidis.脑膜炎奈瑟菌FrpB外膜铁转运蛋白的重折叠、纯化及结晶
Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Feb 1;68(Pt 2):231-5. doi: 10.1107/S1744309111056028. Epub 2012 Jan 27.
10
Capsular polysaccharide vaccine for Group B Neisseria meningitidis, Escherichia coli K1, and Pasteurella haemolytica A2.B 群脑膜炎奈瑟球菌、大肠杆菌 K1 荚膜多糖疫苗和嗜肺巴氏杆菌 A2 荚膜多糖疫苗。
Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):17871-5. doi: 10.1073/pnas.1114489108. Epub 2011 Oct 24.

本文引用的文献

1
A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.一项关于 B 群脑膜炎奈瑟球菌缺失 lpxL1 和 synX 、过表达因子 H 结合蛋白、两种 PorA 以及稳定 OpcA 表达的天然外膜囊泡疫苗的 1 期研究。
Vaccine. 2011 Feb 4;29(7):1413-20. doi: 10.1016/j.vaccine.2010.12.039. Epub 2011 Jan 1.
2
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.多中心、开放性、随机、对照二期临床试验，研究在婴儿期接种含和不含外膜囊泡的新型重组 B 群脑膜炎球菌疫苗的效果。
Clin Infect Dis. 2010 Nov 15;51(10):1127-37. doi: 10.1086/656741. Epub 2010 Oct 18.
3
Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.B 群脑膜炎奈瑟氏球菌抗原的遗传转变与广泛交叉保护疫苗的探索。
Expert Rev Vaccines. 2010 Oct;9(10):1203-17. doi: 10.1586/erv.10.116.
4
Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.两种研究用 B 群脑膜炎球菌疫苗在生命第一年的免疫原性：一项随机对照试验。
Pediatr Infect Dis J. 2010 Nov;29(11):e71-9. doi: 10.1097/INF.0b013e3181f59f6d.
5
Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process.采用基因工程菌株和无洗涤剂纯化工艺改良的脑膜炎奈瑟菌 OMV 疫苗。
Vaccine. 2010 Jul 5;28(30):4810-6. doi: 10.1016/j.vaccine.2010.04.082. Epub 2010 May 16.
6
Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates.侵袭性脑膜炎奈瑟菌分离株中因子 H 结合蛋白模块群的频率和交叉反应杀菌活性的易感性。
Vaccine. 2010 Feb 25;28(9):2122-9. doi: 10.1016/j.vaccine.2009.12.027. Epub 2009 Dec 29.
7
Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus.B群脑膜炎球菌多样性代表性菌株组中三种疫苗成分的分布及遗传变异性
Vaccine. 2009 May 11;27(21):2794-803. doi: 10.1016/j.vaccine.2009.02.098. Epub 2009 Mar 10.
8
Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine.一种新西兰流行株B群脑膜炎球菌外膜囊泡疫苗在婴儿中的免疫原性和耐受性
Pediatr Infect Dis J. 2009 May;28(5):385-90. doi: 10.1097/INF.0b013e318195205e.
9
Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2.源自经基因工程改造的突变菌株的脑膜炎球菌外膜囊泡疫苗，这些菌株可表达来自抗原变异组1和2的补体因子H结合蛋白。
Clin Vaccine Immunol. 2009 Feb;16(2):156-62. doi: 10.1128/CVI.00403-08. Epub 2008 Dec 24.
10
Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis.针对脑膜炎奈瑟菌次要外膜蛋白的抗体的相加和协同杀菌活性。
Infect Immun. 2007 Nov;75(11):5434-42. doi: 10.1128/IAI.00411-07. Epub 2007 Jul 30.